{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:18:27Z","timestamp":1793675907032,"version":"4.5.1"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The complement system, consisting of three initiating pathways\u2014classical, lectin and alternative, is an important part of innate immunity. Dysregulation of the complement system is implicated in the pathogenesis of several autoimmune and inflammatory diseases. Therapeutic inhibition of the complement system has been recognized as a viable approach to drug development and has been successful with the approval of a small number of complement inhibitors for diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis and geographic atrophy. More recently, therapies selectively targeting the alternative pathway (AP), which drives the amplification of the complement responses, are being evaluated for these complement-mediated diseases. Complement Factor B, a serine protease, is a unique component of the AP that is essential for the catalytic activity of AP C3 convertase and AP C5 convertase. Inhibition of Factor B blocks the activity of the alternative pathway and the amplification loop, and subsequent generation of the membrane attack complex downstream; however, it has no effect on the initial activation mediated by the classical and lectin complement pathways. Therefore, Factor B is an attractive target for diseases in which the AP is overactivated. In this review, we provide an overview of Factor B and its critical role in the AP, discuss the benefit-risk of Factor B inhibition as a targeted therapeutic strategy, and describe the various Factor B inhibitors that are approved and\/or in clinical development.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1537974","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T02:00:14Z","timestamp":1739498414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Factor B as a therapeutic target for the treatment of complement-mediated diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"David","family":"Kavanagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201591881","article-title":"Complement activation, regulation, and molecular basis for complement-related diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/imr.v313.1","article-title":"Low-molecular weight inhibitors of the alternative complement pathway","volume":"313","author":"Schubart","year":"2023","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01851","article-title":"Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases","volume":"9","author":"Dobo","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","article-title":"The role of the alternative pathway of complement activation in glomerular diseases","volume":"18","author":"Lukawska","year":"2018","journal-title":"Clin Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31877","DOI":"10.1038\/srep31877","article-title":"MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dobo","year":"2016","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900605","article-title":"Cutting edge: role of MASP-3 in the physiological activation of factor D of the alternative complement pathway","volume":"203","author":"Hayashi","year":"2019","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.214","article-title":"Metabolism of complement factor D in renal failure","volume":"34","author":"Pascual","year":"1988","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701668","article-title":"Contribution of adipose-derived factor D\/adipsin to complement alternative pathway activation: lessons from lipodystrophy","volume":"200","author":"Wu","year":"2018","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.09.005","article-title":"The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification","volume":"47","author":"Harboe","year":"2009","journal-title":"Mol Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1436","article-title":"The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation","volume":"12","author":"de Boer","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747594","article-title":"Alternative complement pathway inhibition does not abrogate meningococcal killing by serum of vaccinated individuals","volume":"12","author":"Ispasanie","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732146","article-title":"Alternative complement pathway inhibition abrogates pneumococcal opsonophagocytosis in vaccine-naive, but not in vaccinated individuals","volume":"12","author":"Muri","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1020580","article-title":"Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b","volume":"13","author":"Muri","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180833","article-title":"In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway","volume":"14","author":"Ispasanie","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03485-w","article-title":"Complement catalyzing glomerular diseases","volume":"385","author":"Zipfel","year":"2021","journal-title":"Cell Tissue Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.10.015","article-title":"Complement-mediated kidney diseases","volume":"128","author":"Poppelaars","year":"2020","journal-title":"Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02510-4","article-title":"Complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH): A systematic review and expert opinion from central Europe on special patient populations","volume":"40","author":"Bodo","year":"2023","journal-title":"Adv Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00417-3","article-title":"Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE","volume":"17","author":"Prendecki","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B27","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION FABHALTA\u00ae (iptacopan) capsules, for oral use\n          \n          \n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"B29","unstructured":"Novartis receives FDA accelerated approval for Fabhalta\u00ae (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)\n          \n          \n          2024"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-810420-0.00014-6","article-title":"Chapter 14- Factor B","volume-title":"The Complement FactsBook (Second Edition)","author":"Laskowski","year":"2018"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system","volume":"188","author":"Lubbers","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0700","article-title":"Complement factor H is expressed in adipose tissue in association with insulin resistance","volume":"59","author":"Moreno-Navarrete","year":"2010","journal-title":"Diabetes"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.344","article-title":"Regulated expression of complement factor B in the human kidney","volume":"50","author":"Welch","year":"1996","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0758","article-title":"The acute phase response in Sicilian patients with boutonneuse fever admitted to hospitals in Palermo, 1992-1997","volume":"42","author":"Vitale","year":"2001","journal-title":"J Infect"},{"key":"B35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev.iy.13.040195.001425","article-title":"Transcriptional regulation of complement genes","volume":"13","author":"Volanakis","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.263418","article-title":"Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein","volume":"286","author":"Hourcade","year":"2011","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.184","article-title":"Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex","volume":"28","author":"Janssen","year":"2009","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195821","article-title":"Structures of C3b in complex with factors B and D give insight into complement convertase formation","volume":"330","author":"Forneris","year":"2010","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135758","article-title":"C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-\/- Cfd-\/- mice","volume":"5","author":"Zhang","year":"2020","journal-title":"JCI Insight"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1755","article-title":"Structure of complement fragment C3b-factor H and implications for host protection by complement regulators","volume":"10","author":"Wu","year":"2009","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase of complement by the plasma protein beta1H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2249.2007.03553.x","article-title":"Translational mini-review series on complement factor H: structural and functional correlations for factor H","volume":"151","author":"Schmidt","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1306326","article-title":"Deficiency in complement factor B","volume":"369","author":"Slade","year":"2013","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00906-3","article-title":"A novel case of complement factor B deficiency","volume":"41","author":"Gauthier","year":"2021","journal-title":"J Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/1546-0096-6-S1-P266","article-title":"Complement factor B deficiency associated with recurrent asceptic meningitis","volume":"6","author":"Dehoorne","year":"2008","journal-title":"Pediatr Rheumatol Online J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812584106","article-title":"Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B","volume":"106","author":"Montes","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","unstructured":"COMPLEMENT FACTOR B; CFB"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690821","article-title":"Factor D inhibition blocks complement activation induced by mutant factor B associated with atypical hemolytic uremic syndrome and membranoproliferative glomerulonephritis","volume":"12","author":"Aradottir","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv054","article-title":"Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B","volume":"30","author":"Imamura","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013070796","article-title":"Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01012-09","article-title":"Enhanced susceptibility to acute pneumococcal otitis media in mice deficient in complement C1qa, factor B, and factor B\/C2","volume":"78","author":"Tong","year":"2010","journal-title":"Infect Immun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.16.8720","article-title":"Abrogation of the alternative complement pathway by targeted deletion of murine factor B","volume":"94","author":"Matsumoto","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/imr.v313.1","article-title":"Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP\/AL)-driven Complement-mediated Diseases","volume":"313","author":"Gibson","year":"2023","journal-title":"Immunol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B","volume":"164","author":"Watanabe","year":"2000","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"key":"B64","unstructured":"Novartis presents latest Phase III Fabhalta\u00ae (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo\n          \n          \n          2024"},{"key":"B65","volume-title":"Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT)","year":""},{"key":"B66","volume-title":"Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)","year":""},{"key":"B67","volume-title":"Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G)","year":""},{"key":"B68","volume-title":"Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)","year":""},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative omplement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.04.029","article-title":"Design and rationale of the APPELHUS phase 3 open-label study of factor B inhibitor iptacopan for atypical hemolytic uremic syndrome","volume":"8","author":"Kavanagh","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"TaRgeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study","volume-title":"Kidney Int Rep.","author":"Rizk","year":"2023"},{"key":"B72","first-page":"402","article-title":"Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway","volume-title":"Immunol Rev","author":"Dreismann","year":"2023"},{"key":"B73","article-title":"Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice","volume-title":"Immunobiology","author":"Grossman","year":"2016"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.06.154","article-title":"Pharmacodynamic efficacy of IONIS-FB-LRX, a complement factor B antisense oligonucleotide, in a phase 1 clinical study","volume":"102","author":"McCaleb","year":"2018","journal-title":"Mol Immunol"},{"key":"B75","volume-title":"An Exploratory Trial of an Investigational RNA Therapeutic, IONIS-FB-LRx, for Treatment of IgA Nephropathy. ABSTRACT: SA-PO714","author":"Barbour","year":"2022"},{"key":"B76","volume-title":"A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)","year":""},{"key":"B77","volume-title":"A Trial of HRS-5965 Tablets in Primary IgA Nephropathy","year":""},{"key":"B78","volume-title":"A Study of Single-dose MY008211A in Healthy Adults","year":""},{"key":"B79","doi-asserted-by":"publisher","first-page":"152106","DOI":"10.1016\/j.imbio.2021.152106","article-title":"A small fragment of factor B as a potential inhibitor of complement alternative pathway activity","volume":"226","author":"Sultan","year":"2021","journal-title":"Immunobiology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402013","article-title":"A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models","volume":"193","author":"Subias","year":"2014","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02528","article-title":"Blocking complement factor B activation reduces renal injury and inflammation in a rat brain death model","volume":"10","author":"Jager","year":"2019","journal-title":"Front Immunol"},{"key":"B82","article-title":"Arrowhead pharmaceuticals initiates phase 1\/2a study of ARO-CFB for treatment of complement mediated kidney disease","year":"2024"},{"key":"B83","unstructured":"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000200","article-title":"Identification of Complin, a novel complement inhibitor that targets complement proteins factor B and C2","volume":"184","author":"Kadam","year":"2010","journal-title":"J Immunol"},{"key":"B85","volume-title":"Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy","year":""},{"key":"B86","volume-title":"Study of NM8074 in Adult C3 Glomerulopathy Patients","year":""},{"key":"B87","volume-title":"Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","year":""},{"key":"B88","volume-title":"Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy","year":""},{"key":"B89","volume-title":"Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris","year":""},{"key":"B90","unstructured":"NovelMed Announces Interim Positive Results from Its Phase I Clinical Trial of NM8074, a Bb Complement Alternative Pathway Blocker Antibody"},{"key":"B91","volume-title":"A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","year":""},{"key":"B92","volume-title":"Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","year":""},{"key":"B93","article-title":"Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria","year":""},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009028","article-title":"SAR443809: A selective inhibitor of the complement alternative pathway, targeting complement factor bb","volume":"7","author":"Rajagopal","year":"2023","journal-title":"Blood Adv"},{"key":"B95","volume-title":"A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults","year":""},{"key":"B96","volume-title":"Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease","year":""},{"key":"B97","unstructured":"SOLIRIS\u00ae (eculizumab) injection, for intravenous use. HIGHLIGHTS OF PRESCRIBING INFORMATION\n          \n          \n          \n          2020"},{"key":"B98","unstructured":"ULTOMIRIS\u00ae (ravulizumab-cwvz) injection, for intravenous use.HIGHLIGHTS OF PRESCRIBING INFORMATION\n          \n          2022"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209692","article-title":"Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab","volume":"104","author":"Granoff","year":"2019","journal-title":"Haematologica"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.07.025","article-title":"Improving clinical trials for anticomplement therapies in complement-mediated glomerulopathies: report of a scientific workshop sponsored by the national kidney foundation","volume":"79","author":"Bomback","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.600656","article-title":"An \"Outside-in\" and \"Inside-out\" Consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases","volume":"14","author":"Morgan","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2009.10.006","article-title":"MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation","volume":"215","author":"Skjoedt","year":"2010","journal-title":"Immunobiology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12500","article-title":"Complement component C3 - The \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol Rev"},{"key":"B104","doi-asserted-by":"publisher","first-page":"104956","DOI":"10.1016\/j.jbc.2023.104956","article-title":"Struijf EM, De la O Becerra KI, Ruyken M, de Haas CJC, van Oosterom F, Siere DY et al. Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies","volume":"299","year":"2023","journal-title":"J Biol Chem"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707159","article-title":"Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population","volume":"12","author":"Cyprian","year":"2021","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"B107","volume-title":"Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","year":""},{"key":"B108","volume-title":"Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +\/- V","year":""},{"key":"B109","volume-title":"A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration","year":""},{"key":"B110","volume-title":"A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG","year":""},{"key":"B111","volume-title":"A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy","year":""},{"key":"B112","volume-title":"GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)","year":""},{"key":"B113","volume-title":"Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","year":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T02:00:34Z","timestamp":1739498434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2025.1537974"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1537974","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"article-number":"1537974"}}